theme catalyst
set key sector theme stock idea compani catalyst
see move transit growth see
optimist outlook recent drug launch move initi
launch phase enter period strong increment profit gener
valuat undemand us premium vs eu major high
global major pharma trade ev/npv broadli line
long-run averag notabl eu major npv trade
signific discount us major npv believ diverg
unwarr mid-term ep revenu growth cagr similar
 readout favour eu major head expect
lower valu global pivot trial readout vs vs
howev eu compani see signific step-up valu
us major readout fall
new launch momentum critic stock perform
siponimod seysara expect continu strong
momentum tagrisso ocrevu fasenra ozemp cosentyx
hemlibra shingrix depend increment capac
us polit pressur remain key sector overhang focu
much action move forward beyond rhetor develop
includ impact price transpar initi california
januari list price increas ii part donut hole reform iii
progress part price control part protect categori
brexit survey azn gsk ipsen expos uk-bas
manufactur challeng compani confid prepar
stock idea growth remain posit astrazeneca lonza
almiral sanofi merck kgaa prefer valu stock
figur signific valu pivot trial readout product remain focu
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
 number readoutspeak sale potenti prob pivot postivepivot mixedpivot negativepivot pendingno drugsu compani ex biotech eu compani ex biotech select charl martineau pm univers toronto
figur pharmavalu ev/npv time
credit suiss estim note takeda shire repres sum
previous publish npv without synergi takeda acquisit shire
approv decemb
figur signific valu pivot trial readout product remain focu
ev/npvavg eu majorsavg us majorsavg eu specavg myersrochenovartisgsktakeda shireaznnovonordisk lillyabbviej jmerckpfizerpharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract kgaaalkermesviforallerganlundbeckucboriongrifolsipsenrecordatipharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract attract number readoutspeak sale potenti prob pivot postivepivot mixedpivot negativepivot pendingno drugsu compani ex biotech eu compani ex biotech select charl martineau pm univers toronto
stock idea
sanofi outperform tp reiter outperform sanofi stock
continu screen cheapest major pharma ev/npv trade
discount npv forecast broadli line consensu sale
ep see strong underli valu sanofi given rel high
exposur older cash gener tail asset beyond patent shock
assum regeneron jv remain invest mode see
lower payment back regeneron consensu expect new cfo
bring fresh impetu simplif strategi look forward hear
prioriti new head
azn outperform tp astrazeneca one top pick larg cap
pharma believ compani start signific period product
growth ahead consensu sale growth driven higher tagrisso
higher em sale farxiga reflect stronger class sale forecast
also ahead consensu earn catalyz shift toward
specialti tagrisso imfinzi allow good underli margin uplift
core ebit margin cs vs con believ anoth year
pipelin option peak potenti probabl adj
total peak eu come azn
bayer outperform tp bayer offer compel valu discount
fair valu due glyphos litig fear monsanto execut risk
hand litig case expect complet first round court
hear expect scienc prevail longer term number
line compani guidanc assum swing agrochem cycl
merck kgaa outperform tp merck kgaa one cheapest
european specialti pharma compani coverag trade
discount npv merck lead posit life scienc tool key driver
option
avelumab believ mavenclad under-valued asset
consensu sale merck kgaa trade pe
discount eu specialti peer discount global life scienc tool
mavenclad bispecif
lonza outperform tp believ lonza carri impress
month share price perform ahead consensu
sale earn lonza continu benefit unpreced
demand space clear leader believ new initi
add capac phase disciplin invest also boost
growth lonza trade pe premium eu specialti
pharma howev compar peer lonza trade discount
almiral outperform tp believ manag team success
execut medic dermatolog strategi us believ allergan
deal strateg sound highli accret believ market
underestim sale seysara consensu sale
addit believ consensu underappreci margin leverag
allergan acn drug psoriasi product transform top line growth
increas margin mix time cs ebitda margin vs consensu
tabl content
stock idea
tabl content
eu major consensu sale ep dividend
specialti consensu sale ep div
page intent left blank
recent launch
profit
see move transit growth sector outlook
characteris year ahead transit patent expiri
uncertain launch momentum domin concern see
optimist outlook recent drug launch move initi launch
phase enter period strong increment profit gener histor
rule thumb primari care product break even year specialti
care drug year consequ cosentyx dupix entresto ocrevu
tagrisso see meaning improv contribut margin
figur set sale growth us market broken volum
price mix/trad sector pe seen larg reflect us market
growth see sector pe current undemand provid attract
foundat mani stock acceler earn growth trend
recent product launch move increment profit given correl
pe sale growth continu see new product revenu momentum key
stock perform set detail expect page
includ launch forecast dupix asthma fasenra ozemp aimovig
launch invest profit leverag key driver
continu high sg assumpt think drive lower
consensu short-term ebit margin believ compani maxim
earli launch invest drive long-term npv launch asset includ
dupix asthma aimovig us mavenclad siponimod seysara
expect oral semaglutid launch given late approv
figur consensu pharma pe rel non-financi market eu us japan
figur us pharma sale growth time volum valu
credit suiss estim price decemb
figur compar valuat upsid cs target price credit suiss holt default linker
pharmavalu equiti npv
credit suiss estim credit suiss holt bayer holt linker includ monsanto yet avail
sale growthl ep growthdiv yield sharenpv/ shareabbvi squibb lilli co major averag ex nordisk major averag ex major averag ex specialti differ current price target priceholt defaultholt linkerpharmavalu equiti npvpharmavalu charl martineau pm univers toronto
prefer mid-term valuat metric pharmavalu ev/npv support
view sector valuat undemand global major pharma trade
ev/npv broadli line long-run histor averag see figur
notabl eu major pharma trade signific discount us major pharma
within global group valuat gap two high
find fundament reason justifi differ mid-term ep
revenu growth cagr similar one notabl observ us-domicil
investor much less concern us drug price reform rel eu-bas
investor everyon agre magnitud polit nois us investor
believ system complex chang extrem difficult implement
figur set market-impli valu use pharmavalu npv
pale blue bar x-axi repres premium identifi valu
pipelin pale blue bar x-axi repres discount identifi
figur figur set sensit late stage pipelin readout
npv length bar show potenti move ev/npv late stage
 success compani move bottom bar failur compani
move top bar azn roch highest option within
eu major azn driven larg calquenc head-to-head
imbruvica due expans indic lynparza roch
risdiplam sma polatuzumab dlbcl import beyond
lower probabl alzheim data gantenerumab/crenezumab
signific
figur pharmavalu ev/npv time
figur pharmavalu impli valu time eu major
ev/npvavg eu majorsavg us majorsavg eu specavg ev account identif d/other identifi dunidentif charl martineau pm univers toronto
figur npv sensit success major
figur npv sensit success -spec
myersrochenovartisgsktakeda shireaznnovonordisk lillyabbviej jmerckpfizerpharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract myersrochenovartisgsktakeda shireaznnovonordisk lillyshireabbviej jmerckpfizerpharmavalu ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug kgaaalkermesviforallerganlundbeckucboriongrifolsipsenrecordatipharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract kgaaalkermesviforallerganlundbeckucboriongrifolsipsenrecordatipharmavalu ev/npvlegendev npv valuationshad bar -impact success/failur drug prob dot bar -impact success/failur drug charl martineau pm univers toronto
ratio converg first time year
figur set short mid-term ep growth pe valuat use
consensu cs forecast individu compani data shown
improv ep momentum eu major pharma expect
year ep growth eu major improv significantli cours
sector track deliv ep growth base
consensu mid-to-high singl digit ep growth
eu growth broadli line us major expect us major
show mark slowdown year-on-year benefit trump tax reform
annualis mid-term view consensu assum stabl ep growth
ratio show converg first time sinc januari
improv eu major pharma growth modest pe discount eu group
vs us major mean ratio converg first time last year
figur credit suiss forecast ratio base
yr forwardbiotech major major pe yr ratiosbiotech yr eu major yr us major yr majorsnovnbmyglob majorspfeeu majorsmrkshpazn csazn companybay ratio vs compound-annual-growth-rate ep growth charl martineau pm univers toronto
pe multipl growth data
figur us major pe ep growth figur us major pe ep growth
figur eu major pe ep growth figur eu major pe ep growth
figur biotech pe ep growth
figur biotech pe ep growth
global pivot clinic trial success rate declin
howev probabl still averag sinc
figur show histor peak sale potenti drug pivot data
forecast success rate eu us sector
percentag peak sale potenti posit result saw
sharp overal increas success rate decreas
exclud select remain mostli unchang highlight
proport readout cancer remain high compar histor averag
total valu cancer vs averag sinc
expect decreas
global pharma pivot trial readout eu
pharma expect lower valu pivot trial readout compar
vs despit forecast higher readout eu
pharma vs convers us expect
valu readout decreas
highlight azn trial expect readout could gener peak sale
attribut multipl trial run imfinzi/trem
combin probabl success trial within rang
anticip result lower chanc success high valu
potenti peak sale includ novartiss entresto treatment heart
failure-pef potenti peak prob
declin success rate driven increas innov versu
histor demonstr trend success rate boost
increas de-risk pivot trial link valu pivot
trial came innov drug compar therefor one
might expect success rate decreas
percentag uniqu lowest sinc product known
mechan product line extens key readout due
innov line extens increas
driven product previous proven mechan
potenti offer better efficaci safeti conveni vs averag sinc
given low innov level increas line extens
success rate could strong
figur recent success rate peak sale potenti drug expect show pivot data
 number readoutspeak sale potenti prob pivot postivepivot mixedpivot negativepivot pendingno drugsu compani ex biotech eu compani ex biotech select charl martineau pm univers toronto figur full list select pivot readout potenti blockbust drug
regioncompanydrugindicationtri stagecurr prob econom peak sale mpro adj sale euaznbrilintathemi cv tripl durvalumab/ tremecanc head neck durvalumab/ tremecanc bladder durvalumab/ tremeunresect durvalumab/ tremensclc durvalumab/ tremecanc sclc pancreat adjuv cancer combo anemia close trial ovarian pef heart failur vs muscular chemotnbc bc post kadcyla/ gastric micro myeloma new line combo/fl mapl new line combo/fl metastat tnbc pancreat ovarian tofacitinib atop includ select biotech seper charl martineau pm univers toronto
record year valu fall
strong year approv us new product key line
extens approv expect one year end
forecast peak sale compar peak sale
approv includ biktarvi gilead hiv erleada
prostat takhzyro shire multipl new biolog migrain product
aimovig novartis/amgen ajovi teva emgal line extens
includ tagrisso nsclc azn imfinzi pacif azn keytruda
anticip see step number valu
approv forecast drop expect valu us approv
assum probability-adjust valu vs
expect similar number approvals/lin extens mainli io
first time approv blockbust includ novarti
first gene therapi sma type risankizumab upadacitinib
treatment inflammatori diseas oral semaglutid novo nordisk
treatment type diabet alexion treatment
paroxysm nocturn hemoglobinuria also number potenti key
line extens immuno-oncolog includ tecentriq roch tripl neg
breast cancer small cell lung sclc keytruda merck nmi bladder
cancer sclc gastric cancer hepatocellular carcinoma data
due earli dupix sanofi also see expans adolesc
figur us drug approv nda bla cs estim peak sale potenti
 prob number new launch spot us peak sale yr us lch bar sale nda sale s-nda sale bla sale s-bla sale bla-b sale otherpeak sale us overallu charl martineau pm univers toronto
sanofi dupix asthma dupix approv asthma octob
broadest label biolog treatment launch uptak benefit
solid efficaci subcutan home administr view howev
challeng given strong presenc incumb competitor
xolair roch nucala gsk fasenra azn limit current
relationship san/regn respiratori specialist pulmonologist
limit price flexibl given sanofi uniqu posit atop dermat figur
show expand ramp dupix base forecast us asthma
sanofi dupix atop dermat ad dupix significantli outperform
expect origin forecast start
sale increas ramp exceed expect
expect total dupix sale ad expect launch
moder slightli bolu wareh patient annualis
see growth driven strong repeat treatment refil rate penetr
less sever ad patient increas treatment rate potenti adolesc
approv submit sbla forecast us sale ad
dupix vs azn fasenra vs gsk nucala hard compar figur
show impli project dupix script asthma base sale
expect comparison launch nucala fasenra
howev comparison launch curv could mislead due
sub-optimal captur iqvia categori nucala fasenra requir
administr healthcar profession vs dupix mainli self-
inject expect stronger captur prescript iqvia
highlight fasenra launch track ahead nucala believ reflect
azn target pulmonologist allergi specialist use
prescrib inject wherea believ gsk far concentr
pulmonologist forecast fasenra sale
cse impli rx ramp ad asthma
benchmark cse impli rx ramp
launchweek launchstelaracosentyxtaltzdupixentdupix cse addupix inc launchweek launchnucalafasenradupix csefasenra charl martineau pm univers toronto
azn tagrisso momentum tagrisso remain strong april tagrisso
label broaden includ egfr posit lung cancer patient
set initi approv egfr mutat posit nsclc
uptak new set key driver make tagrisso number one
prescrib egfr therapi new-to-brand prescript nbrx figur
show impli inflect impli forecast increment sale
nsclc expect continu strong uptak due strong phase
data flaura outsid us tagrisso growth benefit
intern roll china approv reimburs
novo nordisk ozemp novo once-weekli launch start
ytd novo obtain two-third formulari access us
prescript strong uptak benefit best-in-class data
posit physician feedback forecast sale figur
show impli prescript demand assum averag price
believ launch reason given ozemp strong profil dtc
campaign novo domin posit market victoza
analysi iqvia data suggest traction improv benefit posit
recommend us heart failur guidelin greater penetr
sale rep key catalyst entresto data hfpef paragon
studi data posit data could provid upsid sale
posit halo hfref patient clinic hf preval hfpef
estim expect continu
current trajectori base us sale forecast vs cse
novarti aimovig may aimovig becam first cgrp inhibitor
fda approv treatment migrain sinc aimovig approv
two cgrp inhibitor approv teva ajovi lilli emgal earli
feedback price per year product
specialti threshold posit earli rebat discuss head
novartis/amgen target high volum specialist primari care
physician us current access posit forecast sale
base current trajectori free drug remain preval
competit launch market limit link revenu prescript
launchweek launchtagrisso cstagrissotarceva launchweek launchvictozaozempicozemp charl martineau pm univers toronto figur entresto cse impli rx ramp
differ cs consensu forecast
highlight differ cs consensu evalu world-wide
forecast key launch product
launchweek launchjardiancepradaxaxareltobrilintaxarelto spafeliquisentrestoentresto cs launchaimovig cseaimovigajovyemg sale cs prob po sale usd mavenclad po mavenclad mavenclad cs prob adj sale cs prob sale usd shingrix cs shingrix charl martineau pm univers toronto figur cs vs consensu tagrisso forecast figur cs vs consensu ozemp forecast
figur therapeut categori news flow
page set catalyst compani coverag event
therapeut categori set figur highlight follow
astrazeneca similar oncolog trial readout key focu area
investor expect first half overal surviv readout
neptun trial look durvalumab
nsclc remain import despit low expect follow high-profil
failur mystic trial look readout well kestrel head
neck provid first data valid tremelimumab also import
reinforc azn leadership parp lynparza readout polo
pancreat cancer profound prostat ovarian beyond
oncolog expect see data roxadustat cv outcom
anemia brillinta cv outcom themi studi diabet also
data etho azn tripl copd expect
gsk catalyst continu domin compani hiv franchis
look see potenti fda ema approv gsk second hiv
semaglutideprior review voucher potenti approv -darolutamid nmcrpc dataazn -roxadustat anemia data cv outcomeazn -imfinzi/ treme kestrel il -rituxan biosimilar celltrion us launchnovo-or semaglutid submissionazn-brilinta cv outcom diabet themi data -trulicitycv outcom detail june -tirzepatid surpass program initiationnovarti -cosentyx prevent nraxspa arrow vs tremfya ucb -bimekizumab ps data cll datasanofi -praluentcv benefit pdufa aprilsanofi -zynquista us reg decisionbay -xarelto voyag pad completionbay -xarelto einstein vtex may -june data-baricitinib atop dermat datagsk mm data potenti fda filinggsk mm combo poc datanovarti approv late marchlundbeck -rexulti bipolar mania nordisk -somapacitan ghd dataroche-herceptin biosimilar us launchgsk -zejula ovarian cancer data -primabmy-nivolumab/ipi part nsclc datasanofi-sutimlimab agglutinin diseas data cadenza/cardin studiesgsk-fostemsavir hiv filingnovarti -entresto paragon hf pef datanovarti -ofatumumab relaps ms datalundbeck -rexulti ptsd datalundbeck -foliglurax parkinson data data rrm sanofi -cablivi acquir ttp pdufagsk -dtg hiv approvalnovarti type sma approvalsanofi datagsk data -captainroch -risdiplam sma data file charl martineau pm univers toronto
cabotegravir rilpivirin also expect present detail
data potenti croi march oncolog key focu area
pivot data bcma zejula prima expect also
expect news flow first potenti approv gener us advair
sandoz product face regulatori decis
novarti number signific catalyst novarti arguabl
biggest event approv type sma pdufa may
mark first gene therapi approv sma multipl
sclerosi expect see approv march data
ofatumumab relaps ms product help maintain novarti
competit ms end second quarter see phase
data cosentyx non-radiograph axial spondyloarthr prevent
head-to-head studi tremfya arrow harder-to-treat patient
resist treatment stelara approv nraxsp would uniqu
would broaden cosentyx use rheumatolog novarti expect alcon spin-
novo nordisk rel signific catalyst novo nordisk
key focu continu ramp weekli
analogu ozemp semaglutid compar lilli weekli trulic
believ novo submit oral sema data fda prioriti review
voucher prv file slightli delay understand novo give
day notic use prv must readi fda inspect file
approv expect end launch earli phase data
investig hemophilia product concizumab expect like
hemlibra drug also non-factor therapi although target tissu factor
pathway inhibitor tfpi rebal clot cascad also biopharma
novo expect detail data second phase trial long-
act growth hormon somapacitan adult data give insight
competit posit given neg phase competitor long-act hgh
versarti opko/pf
roch key catalyst roch us launch biosimilar
rituxan herceptin avastin roch settl celltrion rituxan
herceptin expect enter
respect roch yet settl avastin expect
launch biosimilar although litig could alter time
key approv tecentriq chemo tripl neg breast cancer mtnbc
first io product approv tnbc key readout
data polatuzumab follicular lymphoma entrectinib
sanofi sanofi multipl readout key product dupix
see us approv adolesc atop dermat file nasal polyp
eu approv adult/adolesc asthma data children
year atop dermat could support label expans
pdufa cablivi acquir ttp praluent cv outcom expect
februari april oncolog isatuximab pomalyst data
relapsed/refractori multipl myeloma due also
libtayo cemiplimab eu approv decis basal cell carcinoma expect
libtayo late anti space compani look develop
drug uniqu indic cscc uniqu combin
polit focu lower patient cost
averag annual cost health insur premium us famili
four worker contribut see
figur worker contribut actual flat year-on-year first time
presum due increas use lower premium higher deduct plan
addit prescript cost burden patient continu increas
higher out-of-pocket maximum greater use deduct cost-
share mechan includ copay coinsur figur
presid trump blueprint unit focu white hous fda hh
may octob presid trump set seri propos aim
tackl high drug price us
 seen mani prior attempt politician tackl us drug price
littl success seem notabl us propos reflect
shift focu issu high list price alon consid
pervers system includ rebat role pharmaci benefit
 presid trump also abl align agenda hh fda
market taken relief immedi
consequ pharma
see potenti meaning
consequ medium term like
includ greater formulari manag medicar switch
drug part part could drive greater competit
pressur certain compani posit off-set could point sale
rebat could push volum driven improv patient afford
democrat control hous may slow chang follow
novemb mid-term elect democrat regain control us hous
repres histor note democrat focus
fda safeti patient access may act slow presid
trump blueprint chang propos especi limit access
figur annual cost famili health insur figur percentag worker deduct
averag health insur premium famili cover worker contributionemploy cover workersani deduct charl martineau pm univers toronto
donut hole chang
bipartisan budget come forc aim
reduc donut hole patient cost medicar part patient cost
donut hole fall drug cost achiev
manufactur cost increas
analysi suggest high cost drug could benefit chang due
improv afford drug potenti boost volum time
compani expos low cost drug like see one-off neg impact
compani quantifi impact donut hole chang
figur commentari impact donut hole chang part
impact estim earli specif chang yet known
impact estim inclus viiv factor intern forecast
group sale impli
impact estim
protect categori part
novemb releas propos allow greater flexibl negoti
discount drug protect therapeut class current six
immuno-suppress oral cancer drug
propos includ administr blueprint may would
allow use prior author step therapi allow exclus
drug new formul older single-sourc drug price
drug increas inflat
estim averag us rebat drug across payor exclud oral
cancer comparison estim rebat protect
categori meaning lower hiv drug see rebat ryan
white program also support patient co-pay oral cancer rebat
minim howev brand drug protect categori
typic rebat anti-psychot anti-depress epilepsi
propos claim typic commerci rebat protect
categori drug part
figur show exposur categori medicar part antipsychot
anti-depress greatest exposur part hiv
epilepsi next expos oral cancer exposur
lowest nevertheless would expect move chang coverag
option part affect formulari manag commerci plan time
lundbeck ucb azn novarti expos eu pharma figur
show npv exposur pharma compani protect categori
lundbeck greatest exposur npv major drug
portfolio either anti-psychot anti-depress ucb signific
exposur due drug epilepsi azn novarti expos due
npv exposur oral oncolog drug tagrisso mekinist/tafinlar
respect would also highlight gsk due hiv exposur group
detail pleas see compani exposur evolv pressur
protect categori part
figur npv exposur protect categori
medicar part
figur prescript share payor protect
greater manag medicar part expens
octob presid trump hh set seri propos reduc
cost medicar part outpati drug elderli three
main compon shift reimburs part drug base
add-on fee averag sell price asp fix payment model
incorpor private-sector vendor system purchas distribut
part drug increas competit potenti extract discount
manufactur leverag price determin us
price variou drug
model within center medicar medicaid innov cmmi
would need legisl action implement propos
propos would phase five year start initi appli
countri initi focu single-sourc product
differ us ex-u price notic
roch bristol expos larg cap pharma previous publish
note score sensit compani variou reform
present administr blueprint drug price shown figur
roch bristol-my two compani expos
medicar part exposur rest compani
us pharma sale alreadi seen signific pushback propos
industri group phrma expect much debat
propos implement
detail pleas see pharma food thought analysi part
kgaabmysanofiproport pharma npv expos protecetd categoriesor cancerantipsychotics/antidepressivesepilepsytrx charl martineau pm univers toronto figur us pharma sale exposur medicar part d/b medicaid commerci
us net price still posit driver earn
compani analysi suggest gross price rise ytd
net us price rise differ driven increment sale
level net price growth net contribut us price
suggest analysi pharma food thought mth rebat
figur us sale weight list price rise
us pharma sale payoru part bu medicaidu part du commercialavg us rx sale mlist price charl martineau pm univers toronto
astrazeneca gsk
ipsen appear
risk uk-bas
uk-bas manufactur key risk mitig
survey compani coverag regard revenu cost exposur
uk market presenc key product manufactur plant countri
hard brexit risk border custom clearanc delay well uncertainti
transfer qualiti control test eu market astrazeneca gsk ipsen
appear risk manufactur challeng compani believ
plan place off-set
proport compani sale cost uk manufactur key product uk sole suppli conting brexit share envisag global suppli constraint hard brexit publish cost estim impact brexit astrazenecasal sale cost compani product manufactur ukdetail plan focus safeguard access suppli batch-releas test duplic sweden eu move wk stock uk wk eu appropri plan spent plan datebayersal commentnono commentnono commentgsksal staff global pharma manufacturingsuppli continu key prioriti expand eu retesting/certif move market authoris eu entiti updat packag continu suppli top prioriti secur addit warehous one time next year year thereafternovartissal commentno commentplan hold higher inventori across portfoliono comment sever impact compani performancenovo nordisksal commerci affili onlyno manufacturingno contig plan plan hold higher uk inventori across portfolionoth disclosedrochesal place detail public materi rochenonot materialsanofisal staff sitesnoadvanc plan place plan transfer eu qualiti control requir addit warehous capac secur stock level increas week nonoth disclosedshiresal materialcost materialnono commentnono commentalmirallsal action plan place prepar deal scenarioconting placenoth disclosedgrifolssal contig plan non-materialnono impacthikmasal immateri nonono commentnoth disclosedipsensal employe sitesdysport sole supplyadvanc prepar batch control/releas eu move dublin/dreux chang distribut channel increas stock level uk eu transfer market authoris eu mkt eu officesplan place happen continu dysport suppli key prioriti specif disclosedlonzasal employe pharma/bio spec ingredi locationsact monitor develop potenti impact scenario plan prepar place global manufactur footprint pb si support mitig potenti impact increas si inventori eu warehous advanc work pb custom avoid disrupt noth disclosedlundbecksal growthcost commentnonon-materialnono impactmerck kgaasal low singl digit cost employe locationsno commenttask forc place address suppli chain regulatori qualiti safetycentrally-coordin respons across bu plan inventori level ensur disrupt impact much limit orionsal small cost commentnono commentno commentno specif disclosedrecordatisal minor cost commentnonono commentno impactucbsal sale cost small nouk govn statement align eu regul ema licens batch test offset concernschang made limit impactnoth charl martineau pm univers toronto on-going patent
litig key
uncertainti
focu roch us eros
see first us biosimilar entri rituxan herceptin avastin
roch guid expect biosimilar competit rituxan
herceptin avastin figur set summari key potenti
biosimilar player market forecast revenu eros rituxan
herceptin avastin partli reflect io competit avastin
well biosimilar
litig submarin patent litig outcom key uncertainti
around biosimilar launch dynam especi us result
present roch highlight invest legal team defend patent
estat set understand roch ip settlement date
unclear whether biosimilar competitor intend launch risk settlement
made
global settlement rituxan herceptin avastin understand
roch settl ip litig one parti rituxan teva/celltrion
two herceptin mylan/biocon term date launch
public although believ roch guidelin biosimilar entri broadli
match settlement rituxan herceptin roch settl
anyon avastin ip roch claim infring patent
key factor watch understand time avastin
approv biosimilar rituxan herceptin avastin
fda approv one biosimilar rituxan herceptin avastin
teva/celltrion amgen/allergan respect hope gain approv
three product herceptin avastin rituxan
teva/celltrion merck/samsung
amgen/allergan also expect approv herceptin biosimilar
file fda
figur detail roch biosimilar competit cs forecast
productroch estimate companyproductfda statussettl roch trial datelaunch date cse/conscommentscelltrion/tevatruximayi licens entri disclos launch date approv form sep bsufa docket del district court indic two parti dismiss litig on-going licens entri disclos launch date ect first marketcelltrion/tevaherzuma resub jun on-going ini due manufactur plant issu resolv cse approv apr resubmit oct bsufa on-going ini tech info need ect resolv target launch dateamgen/allergankanjinti jun lawsuit on-going ini expect impact launch planmerck/samsungontruzantsubmit ongoingamgen/allerganmvasiylawsuit on-going ini aug bsufa posit on-going evalu detailsrituxanherceptinavastinc us sale growth charl martineau pm univers toronto
explor impact biosimilar far europ
eros rate brand product due biosimilar competit
vari across product region
figur show eros rate sale brand product europ
sinc introduct biosimilar rituxan shown greatest rate declin
sale rel tnf remicad enbrel fifth quarter post
biosimilar launch sale declin reach herceptin competit
start show declin second quarter competit
roch said expect similar pattern declin rituxan herceptin
defenc greater penetr subcutan formul
higher number biosimilar competitor
higher rate eros rituxan explain due level
competit biosimilar addit biosimilar price discount also
similar product uk germani major
biosimilar far discount nordic region part europ
believ episod natur oncolog product rituxan may
make easier switch market share toward biosimilar chronic
product tnf chronic inflammatori diseas switch stabl
patient brand tnf product could difficult particularli interest
rituxan initi herceptin eros strong vs biosimilar
subcutan formul herceptin sale less rituxan
time money
current protect save healthcar system
subcutan product much
us anoth
explan would group hospit purchas preval
oncolog sector tender widespread easier implement
figur yoy sale eros europ number brand product post
biosimilar launch design number biosimilar
compani data credit suiss estim row europ remicad europ russia turkey enbrel develop
growth sinc biosimilar entryquart biosimilar launchesremicad charl martineau pm univers toronto figur uk germani price comparison vs biosimilar
compar european eros us
experi pattern biosimilar eros us significantli less
europ europ approv biosimilar product differ brand drug
wherea us approv launch due patent protect
us eros jnj remicad biosimilar extraordinarili low sale
vs pre biosimilar launch wherea sale drug treat
neutropenia commonli associ chemotherapi erod significantli
even row us sale vs pre biosimilar launch
remicad su septemb claim contract
health insurers/pbm remicad anticompetit block sale
pfizer biosimilar claim relat rebat offer insurers/pbm
remicad particularli commerci market volum medicar
market remicad partli cover part claim tie
high level rebat portfolio product coerc payer agre
reimburs biosimilar drug rebat block product market
new phenomenon system rebat caus pervers incent
favour rebat difficult penetr market
player establish posit previous set believ
humira exampl gain domin posit us link
page novarti cosentyx current tri build rebat barrier
psoriasi biolog thought rebat
fda concern futur biosimilar invest may curtail us
system find effici way switch market share biosimilar
believ us system adjust multipl effort chang
on-going effect could remov rebat safe harbor
provis remov rebat system
limit financi incent within hospit set favour
think import highlight switch brand neupogen
biosimilar us contrast remicad sale
declin yoy sinc firth quarter biosimilar zarzio launch sale
level prior zarzio launch three year ago note
took half year zarzio approv biosimilar realli start gain
prescrib reimburs differ set remicad
similar set rituxan herceptin avastin
biosimilar provid subcutan pre-filled syring
administ healthcar profession patient understand
major purchas done via hospit directli
reimburs payer like herceptin rituxan market
differ remicad commerci market typic hospit financi
incent keep prescrib brand product reduc
medicar part exampl neuopogen sale reimburs
drug cost brand biosimilar plu brand list price
asp establish gener month launch formula meant
prevent incent prescrib brand higher asp
therefor hospit doesnt earn money brand
hospit physician/formulari committe drive switch biosimilar
understand major hospit use group purchas organ
purchas drug highli concentr market three larg
gpo control hospit drug volum gpo effect drive
price inject gener due abil bulk buy howev
discuss gpo highlight perceiv role forc
switch physician toward biosimilar physician committe within hospit
expect decid whether switch instruct gpo purchas
cur vs adjunct therapi one area analog vs
herceptin avastin rituxan may fall reflect therapeut util
use adjunct therapi combat effect chemotherapi
deplet blood cell effect address side effect treatment
contrast herceptin cur patient earli breast cancer
rituxan cure dlbcl lymphoma patient could drive hesit
physician switch biosimilar determin efficaci equival
clearli role fda approv mylan herceptin biosimilar trial show
effect herceptin need realist year
commerci experi herceptin may influenc physician prescrib
earli year biosimilar launch
launch yoy design number
biosimilar
growth sinc biosimilar entryquart biosimilar launchesu growth sinc biosimilar entryquart biosimilar launchesu sale iqvia unitsrenflexi tev/cel inflectra remicaderemicad report us sale iqvia unitsnivestym zarxio sandoz neupogenneupogen report us charl martineau pm univers toronto
unalloc eu pharma
section look utilis free cash flow sector show
free cash flow determin manag choos invest cash
flow identifi amount invest four key area
expens capitalis via collabor acquisit
 dividend share repurchas overal univers compani
gener adjust
spent acquisit invest
captur earn paid dividend made
net share repurchas ad net debt
forecast increas adjust next five-year
period forecast increas invest
increas dividend current model share
repurchas around half rate achiev prior year lead
free cash flow across univers unalloc current assum pay
debt
figur figur look impact histor forecast ep
buyback particular model impact alloc current unalloc
free cash flow fund addit share repurchas compani
novowher alreadi forecast excess free cash flow use buyback
differ minim also show tsr data ad benefit
figur histor use adjust cash flow
figur futur use cash flow
sectoru use adj flowdividendr adj tax cap dshare repurchaseacquisitionsunalloc fcfadj sectoru sectormajorspecialtyjapanev/npv cse use adj free flowdividendr adj tax cap dshare repurchaseacquisitionsunalloc fcfadj charl martineau pm univers toronto figur histor yr compound-annual-growth-rate ep growth show contribut buyback
figur futur yr compound-annual-growth-rate ep growth potenti benefit use unalloc extra
figur total sharehold return ep growth plu dividend impact potenti addit
compound-annual-growth-rate growth ex impact share buyback impact histor share buybacksc ep compound-annual-growth-rate growth ex impact share buyback impact forecast share buybacksregear balanc sheet end buybackc forecast ep gwth buy back ep growth ex impact share buyback impact forecast share buybacksforecast dividend yieldincreas buy-back fcfc forecast ep charl martineau pm univers toronto
eu major consensu sale ep
figur eu major merck kgaa sale growth p/sale
figur eu major merck kgaa ep growth price-to-earnings
figur eu major dividend index yield
kgaamkt cap /c sale squar group sale growth model fx barsc sale bar sale bar market cap cs sale kgaap cs ep dot group ep growth lc bar cs ep bar ep bar cs kgaac dividend yield dot div index cs lc bar cs div index div index div charl martineau pm univers toronto
specialti consensu sale ep div
figur eu specialti sale growth p/sale
figur eu specialti ep growth price-to-earnings
figur eu specialti dividend index yield
cap cs sales-squar group sale gwth model fx barsc sale bar sale bar market cap cs sale cs ep dotgroup ep gwth model fx -barsc ep bar ep dividend yield dot divi index bar cs div index div index div charl martineau pm univers toronto
sensitivitylowlynparza polopancreat dataimfinzi/trem neptun os databrilinta themi data cv data etho sever copd exacerb data file us/eulynparzaprofound ovarian il combo dataroxadustat anemia dataimfinzilung cancer stage i-iii adjuv databrilintastrok datafarxigaheart failur cvot chronic kidney dataepanovahypertriglyceridaemia datafasenranas polyp datatezepelumabsever dataimfinzi/ treme kestrel il lynparzaolympiaadjuv bc possibl interim trial run molidustat bayer renal anemia japan datahighpric data gu feb xarelto voyag completionxarelto einstein jr completionleverkusen remediationfda re-inspectionearli data -victoriacopanlisib relaps data -chrono data charl martineau pm univers toronto
atop data atla fitusiran hemophilia datapralu cv benefit dyslipidemia pdufa aprillibtayo carc eu approv decisiondupix adolesc ad pdufa marchisatuximab pomdex multipl myeloma data icaria dupix sbla nasal polyposi metastat breast datadupix atop dermat datasutimlimab agglutinin data -cadenza cardinalkevzara ra data inhib cervial data data data dupix adolesc ad eu reg decisiondupix adult/adolescentasthma eu reg decisioncablivi acquir us reg mab asthma poc data sensitivitylowclos takeda charl martineau pm univers toronto
sensitivitylowseysara acn us launch european launchesthermistartegi updateskilarenceeu sensitivitylowlinhaliq non-cf bronchiectasi eu approv full data publicationnext stepsfda approv product plant reloc californiashanghai raa potenti deal closurefibrin sealeant launchsub cu ig launchhighpric purif plantapprovalambar peer review journal publicationamerican societi apheresi meet mayibbi collect center acq charl martineau pm univers toronto
small cell datacabometyx renal data somatulinepotenti news gener sandostatin lar resultsand data trial design start depot schizophrenia file mania data result charl martineau pm univers toronto
spain portug francegivosiran alnlylam outcom data ad applic boardpost closur cvc stake zanipress gener copetit data commencesmidazolam nasal spray seizur data approv decisioneven osteoporosi launcheven osteoporosi eu approv decisionbimekizumab psoriasi file even osteoporosi japan approv decisioncimzia nr axspa us approv charl martineau pm univers toronto
compani mention price
